Skip to main content

Table 2 Clinical and Laboratory Parameters of the Radiographic Axial Spondyloarthritis Patients and the Healthy Donors

From: Enhanced NETosis generation in radiographic axial spondyloarthritis: utility as biomarker for disease activity and anti-TNF-α therapy effectiveness

 r-axSpA patients (n = 30)Healthy Donors (n = 32)P
Clinical parameters
 Women/men, n/n5/2510/220.180
 Age, y46.40 ± 2.4541.06 ± 1.770.080
 BASDAI4.42 ± 0.45 
 BASFI4.73 ± 0.61 
 BASMI3.22 ± 0.31 
 mSASSS19.16 ± 3.86 
 Disease duration, y13.23 ± 2.07 
 Extra-articular manifestations
 ➣ Uveitis0/300/32 
 ➣ Psoriasis0/300/32 
 ➣ IBD0/300/32 
Laboratory parameters
 HLA-B27 (%)26/30 (86.67%) 
 CRP, nmol/L122.57 ± 31.3813.62 ± 3.25< 0.001
 ESR, mm/h19.84 ± 4.097.48 ± 1.000.006
 TNF-α, pg/mL10.89 ± 1.824.02 ± 1.200.021
 IL-1β, pg/mL2.46 ± 0.221.57 ± 0.270.047
Treatments
 NSAIDs (%)28/30 (93.33%) 
 Sulfasalazine (%)2/30 (6.67%) 
  1. Values are presented as mean ± SEM. The data were analyzed using an Independent Samples t test or a Mann-Whitney U test to evaluate statistical significance between r-axSpA patients and healthy donors. Non-normally distributed data. BASDAI indicates Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functionality Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLA, human leukocyte antigen; IBD, inflammatory bowel disease; IL, interleukin; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; NSAIDs, non-steroidal anti-inflammatory drugs; r-axSpA, radiographic axial spondyloarthritis; TNF, tumor necrosis factor